Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer

Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer

The review deals with trials of pegylated liposomal doxorubicin (PLD) used to treat metastatic breast cancer (mBC), including first-line monotherapy, maintenance therapy, combinations with other cytostatics, trastuzumab regimens for a HER-2-positive subvariant, and rescue therapy for intensively pre...

Full description

Bibliographic Details
Main Author:	E. V. Artamonova
Format:	Article
Language:	Russian
Published:	ABV-press 2016-09-01
Series:	Опухоли женской репродуктивной системы
Subjects:	metastatic breast cancer anthracyclines pegylated liposomal doxorubicin
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/492

Similar Items

Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center
by: Salah Mabrouk Khallaf, et al.
Published: (2020-04-01)

Pharmacoeconomics analysis of pegylated liposomal doxorubicin (Caelyx®) in the treatment of patients with metastatic breast cancer at high risk of cardiac events
by: I. S. Krysanov
Published: (2018-05-01)

Pegylated liposomal doxorubicin (PLD) in daily practice—A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer
by: T. Wallrabenstein, et al.
Published: (2023-06-01)

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
by: Yuanyuan Shen, et al.
Published: (2024-12-01)

DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST
by: T. Yu. Semiglazova, et al.
Published: (2017-09-01)

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics
by: Wei Zhuang, et al.
Published: (2022-04-01)

Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy
by: Ping Huang, et al.
Published: (2022-08-01)

An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population
by: Yang SHEN, Zhixiang SHEN, Bin JIANG, et al.
Published: (2009-12-01)

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
by: Ondřej Kubeček, et al.
Published: (2015-07-01)

Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer
by: Xia LIU, et al.
Published: (2009-12-01)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
by: Brian A. Jonas, et al.
Published: (2023-01-01)

PEGylated versus Non-PEGylated pH-Sensitive Liposomes: New Insights from a Comparative Antitumor Activity Study
by: Shirleide Santos Nunes, et al.
Published: (2022-01-01)

A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer
by: Yinjuan Li, et al.
Published: (2022-12-01)

Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review
by: Soumya Ranjan Satapathy, et al.
Published: (2022-01-01)

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
by: Hiroyuki Yoshida, et al.
Published: (2023-07-01)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
by: Saba Dadpour, et al.
Published: (2022-09-01)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
by: Mohsen Ghaferi, et al.
Published: (2022-10-01)

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
by: Haoqi Wang, et al.
Published: (2022-07-01)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021-01-01)

Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
by: Kenan Aloss, et al.
Published: (2023-03-01)

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
by: Xin-Ru Li, et al.
Published: (2022-08-01)

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
by: Eleonora Ghisoni, et al.
Published: (2019-02-01)

The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials
by: Xin-Ru Li, et al.
Published: (2021-03-01)

Pegylated Liposomal Doxorubicin (Caelyx<sup>®</sup>) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial
by: Silvia Dellapasqua, et al.
Published: (2021-12-01)

Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer
by: J.N. Moreira, et al.
Published: (2004-08-01)

Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report
by: Sonia Rodriguez-Ramirez, et al.
Published: (2022-05-01)

Pegylated liposomal doxorubicin combined with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory solid tumor: a single-arm, open-label, phase I studyResearch in context
by: Suying Lu, et al.
Published: (2024-07-01)

Quantitative Cryo-TEM Reveals New Structural Details of Doxil-Like PEGylated Liposomal Doxorubicin Formulation
by: Rickard Nordström, et al.
Published: (2021-01-01)

The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma
by: Li Li, et al.
Published: (2023-02-01)

Successful avatrombopag combined with cyclosporine treatment for carboplatin/pegylated liposomal doxorubicin/bevacizumab-induced acquired amegakaryocytic thrombocytopenia in a patient with recurrent ovarian cancer: case report
by: Weikang Meng, et al.
Published: (2024-02-01)

Empowering Cancer Therapy: Comparing PEGylated and Non-PEGylated Niosomes Loaded with Curcumin and Doxorubicin on MCF-7 Cell Line
by: Shaghayegh Saharkhiz, et al.
Published: (2023-10-01)

Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade
by: Baoyuan Zhang, et al.
Published: (2024-02-01)

Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
by: I. A. Pokataev, et al.
Published: (2015-11-01)

The Basement Membrane in a 3D Breast Acini Model Modulates Delivery and Anti-Proliferative Effects of Liposomal Anthracyclines
by: Tabea Wiedenhoeft, et al.
Published: (2020-09-01)

Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)
by: Jen-Ruei Chen, et al.
Published: (2008-09-01)

Maleimide-Functionalized Liposomes: Prolonged Retention and Enhanced Efficacy of Doxorubicin in Breast Cancer with Low Systemic Toxicity
by: Chuane Tang, et al.
Published: (2022-07-01)

Characterization and in vitro anticancer study of PEGylated liposome dually loaded with ferulic acid and doxorubicin
by: Andang Miatmoko, et al.
Published: (2025-01-01)

Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma
by: Dino Amadori
Published: (2011-10-01)

Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes
by: Jiani Yuan, et al.
Published: (2017-11-01)

Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes
by: Alberto Gabizon, et al.
Published: (2023-11-01)